drugset / Trial / NCT02187471

Treatment of Pain Associated With Fibromyalgia

NCT02187471

Phase 3 Completed 1301 enrolled Daiichi Sankyo Syneos Health · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The main objective of this trial is to compare change in weekly average daily pain score (ADPS) from baseline to Week 13 in participants receiving either dose of DS-5565 versus placebo. Weekly ADPS is based on daily pain scores reported by the subject that best describes his or her worst pain over the previous 24 hours.

Timeline

Start
2015-01-16
Primary completion
2017-01-06
Completion
2017-01-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirogabalin Small molecule 15 mg Oral
Subject Pregabalin Small molecule 150 mg Oral

Indications